Egypt vs Faroe Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Egypt
0.0%
in 2024
Faroe Islands
0.0%
in 2024
Egypt rank
167th
Faroe Islands rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Egypt
- Faroe Islands
How they compare
Egypt currently reports 0.0% against 0.0% in Faroe Islands, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was Faroe Islands ahead.
Egypt ranks 167th and Faroe Islands ranks 167th of 246 countries.
Egypt has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Egypt | Faroe Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Egypt |
| 2020s | 0.0% | 0.0% | 0.0% | Egypt |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Egypt or Faroe Islands?
- Egypt, at 0.0% against 0.0% in Faroe Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Egypt and Faroe Islands?
- 0.0%, with Egypt ahead.
- How many years of comparable data are there for Egypt and Faroe Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do Egypt and Faroe Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Egypt ranks 167th and Faroe Islands ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.